Arcturus Therapeutics' Inhaled mRNA Therapy ARCT-032 Shows Mixed Results in Phase 2 Cystic Fibrosis Trial
核心洞察
Arcturus Therapeutics (搜索)' ARCT-032, an inhaled mRNA therapy for cystic fibrosis, failed to demonstrate meaningful lung function improvements in its Phase 2 trial, causing shares to plunge 56%.
Despite missing the primary endpoint, high-resolution CT scans revealed encouraging mucus reduction in four of six participants, suggesting potential biological activity.
The company plans to test higher doses and initiate a 12-week study in 2026, while expanding the current trial with a third cohort receiving 15 mg doses.
Arcturus Therapeutics (搜索) Holdings Inc. (NASDAQ: ARCT) experienced a dramatic 56% stock decline on Wednesday following the release of interim Phase 2 results for ARCT-032, an inhaled mRNA therapy for cystic fibrosis that failed to meet its primary endpoint of meaningful lung function improvement.
The San Diego-based biotechnology company reported that ARCT-032 was generally safe and well-tolerated in the second cohort of its ongoing mid-stage trial, which included six adults with Class I cystic fibrosis who received 10 mg daily doses over a 28-day period.
Primary Endpoint Falls Short
The primary analysis comparing lung function (FEV₁) from Day 1 to Day 28 did not demonstrate meaningful improvement. FEV₁, or forced expiratory volume, serves as a key measure of lung function used to assess the effectiveness of cystic fibrosis treatments.
However, Arcturus highlighted encouraging findings from high-resolution CT scans, which revealed reductions in mucus burden in four of the six participants. The company interpreted this as a potential signal of the drug's biological activity, even though it did not translate to measurable lung function gains in the short term.
Exploratory Analysis Reveals Mixed Signals
A post hoc exploratory analysis provided additional insight into the therapy's potential effects. When comparing pre-treatment values with Day 42 measurements, four of the six participants showed modest gains in lung function, with an average absolute increase of 3.8% and a relative increase of 5.1% in percent predicted FEV₁.
Despite these findings, Arcturus acknowledged that the changes fell within the range of natural variability for FEV₁, meaning the results could not be considered statistically significant or definitive evidence of efficacy.
The company also noted that one serious adverse event occurred after the dosing period ended. However, the Data Monitoring Committee determined there was no convincing evidence linking the event to ARCT-032 and approved the trial to continue.
Future Development Plans
Arcturus is expanding its trial to include a third cohort of up to six additional participants, who will receive a higher 15 mg dose of ARCT-032. The company plans to initiate a 12-week safety and preliminary efficacy study involving up to 20 cystic fibrosis patients in the first half of 2026.
Analysts at William Blair pointed to "some potentially promising efficacy signals," particularly noting the mucus reduction data as offering "potential for clinical benefit at [a] high dose." However, they characterized the mucus data as "also slightly mixed," with only four of six evaluated patients showing reductions in mucus volume and in the number of mucus plugs.
Market Response and Clinical Context
The market's response was swift and severe, with Arcturus shares falling to $10.24 in premarket trading, erasing much of the company's earlier 2025 gains. The stock had been up 36.5% year-to-date prior to the announcement.
ARCT-032 is designed to be aerosolized and inhaled as an mRNA therapy that helps restore expression and activity of the cystic fibrosis transmembrane conductance regulator (CFTR (搜索)) gene in the lungs. In patients with cystic fibrosis, the CFTR protein is either deficient or completely absent, resulting in compromised airway function and key symptoms such as inflammation and respiratory failure.
Cystic fibrosis, a genetic disorder characterized by thick, sticky mucus buildup, remains a challenging disease to treat, especially in patients with Class I mutations. Current therapies for cystic fibrosis, such as Vertex Pharmaceuticals' Trikafta and the recently approved Alfytrek (搜索), also address CFTR (搜索) dysfunction.
The company's management remains optimistic that longer-term studies and higher dosing could yield stronger efficacy signals, though the clinical benefit of ARCT-032 remains uncertain based on the current data.